When cost is no longer a barrier: A new chapter for ozone injection in India

Most nights at the diabetes clinic, the conversation eventually comes back to the same word: cost. Not the calories, not the carbs, but the cost. For many patients, drugs like Ozempic have been hovering in an uncomfortable space between medical breakthrough and affordability. Doctors talk about their benefits with cautious optimism. The patient listened, did the math, and quietly returned to his old medications, stricter diet, and longer walks.This equation may change.As the patent for semaglutide (Ozempic) expires on March 20, Indian pharmaceutical giants such as Sun PharmaceuticalZydus Lifesciences, Dr Reddy’s and Natco Pharma are gearing up to launch more affordable versions of the once-exclusive injectable. The high-quality treatments so far may soon become mainstream prescriptions, potentially reshaping India’s fast-growing anti-obesity and diabetes markets.

But cheaper medicines do more than just expand access, they also signal a shift in behavior.Over the years, treatment plans for obesity and type 2 diabetes in India have relied heavily on lifestyle changes: strict diet, exercise regimens and, if necessary, increased pharmaceutical support. Semaglutide, world-renowned for its dual effects on blood sugar and weight loss, introduces a powerful new lever. However, its price ensures that for many it remains a last resort rather than the option they choose first.With the emergence of generic drugs, doctors may reconsider when to prescribe them. Patients who had previously put off treatment can start earlier. There may be a surge in the number of weight management clinics. The precarious balance between lifestyle and medication, between personal discipline and medication assistance, can tip in unexpected ways.The question now is not just whether semaglutide will be cheaper. The question is whether its affordability will quietly redraw the boundaries of how India treats weight, health and responsibility itself.

How does ozone work?

To understand why semaglutide is causing so much excitement and controversy, first we need to understand what it actually does in the body.After we eat, our intestines release a hormone called incretin. These chemical messengers tell the pancreas to produce insulin, which helps move sugar from the blood to cells that need it. They also signal the liver to slow down sugar production and provide a simple message to the brain: You’ve eaten enough.Ozempic works by amplifying natural systems.

Its active ingredient mimics a hormone called glucagon-like peptide-1 (GLP-1), which the body produces after a meal. In people with type 2 diabetes, this response is often attenuated. Semaglutide steps in to strengthen it. When blood sugar rises, it prompts the body to release insulin, reducing excess glucose in the liver and slowing the rate at which food leaves the stomach. The combined effect is more stable blood sugar levels and improved HbA1c readings, which essentially aids in long-term blood sugar control.But the drug’s effects aren’t limited to sugar.GLP-1 also acts on the appetite centers of the brain. It signals satiety, a subtle feeling of fullness that tells people to put down their forks. Semaglutide extends this feeling by creating a more stable and longer-lasting version of this hormone. For obese people, this shift is significant. The constant mental battle around food calms down. Losing weight no longer happens because of constant restraint, but because biology favors them.

Lower prices, wider access – the market will surge

More players will line up to join the fray in the coming months, and with each new entrant, pricing pressure is expected to increase. Until now, India’s weight loss drug market has largely been a playground for high-priced innovative brands, accessible to only a select few. This exclusivity may not last long.Industry observers estimate the current size of the weight loss market at around Rs 1,400 crore and believe this could double within a year if prices soften and supply expands. The medical and consumer demand is clearly there.This momentum isn’t limited to weight-loss drugs. The broader anti-diabetic treatment market grew more than 15% in January, driven primarily by newer, higher-quality treatments, according to research firm Pharmarack. These include Eli Lilly’s Mounjaro, which clocked sales of Rs 112 crore, showing that patients and doctors are willing to embrace innovation, even if it comes at a higher price.“Patent expiration will have a big impact on the market. It is expected to expire on the 20th and by the 21st we have received reports that five different semaglutides will be launched,” said Raman Nath of Nath Medicines.What is changing now is the equation between demand and affordability. If generics can significantly reduce costs, these drugs could shift from niche urban prescriptions to more mainstream treatments. With this shift, the conversation around weight and diabetes management in India may become less about who can afford cutting-edge care and more about how widely it is available.“Doctors prescribe such drugs based on the financial background of the patient. If they see that the patient is financially sound, they will prescribe a drug like Ozempic, otherwise they will prescribe cheaper alternatives,” added Raman.

Beyond Weight Loss: Body Image Issues

Beyond clinics and balance sheets, another, quieter debate is unfolding, one about mirrors, self-worth and the meaning of acceptance.In recent months, the discussion surrounding GLP-1 drugs like Ozempic has expanded beyond blood sugar levels and BMI charts. In social media groups and television debates, some commentators said that if weight loss could be medically reduced, movements centered on body acceptance might start to feel less urgent. The implication is subtle but powerful: If body size can be easily altered through injections, then living in a larger body has the potential to be viewed as a choice rather than a complex combination of biology, environment, and environment.For years, the body positivity movement has stood for dignity and inclusion, no matter how big or small. It rejects the idea that value is measured in kilograms. But as drugs like semaglutide become more visible and potentially cheaper, public perceptions and attitudes may change. If weight loss appears medically achievable, will social tolerance decline?

These medications help regulate appetite and blood sugar; they don’t directly address shame, humiliation, or years of internalized criticism. Research has long shown that body size and body image are closely related. So it’s no surprise that some people may hope that losing weight will also quiet the cacophony inside them or soften the world’s reaction to them.Yet access remains patchy, outcomes vary, and no injection can fully tease out the emotional dimensions associated with food and appearance. As semaglutide becomes more mainstream, India may find itself going through not just a medical shift but a cultural shift, balancing the promise of improved health with the need to preserve empathy, dignity and choice for all body types.“There are two drugs that are sold the most in the country. One is for fairness and the other is for weight loss. Ozempic helps in weight loss. People rarely want to change their lifestyle. To become thin, you have to make a lot of changes and pay attention to your lifestyle and diet. Ozempic makes weight loss easier and that’s why people tend to consume it more,” Raman said.

Risk of misuse

These drugs were originally designed to treat type 2 diabetes, but quickly acquired a second identity: as powerful tools for weight loss. For many patients, the results are dramatic and even life-changing, achieving results that old diets, medications, and fitness fads rarely could. Not surprisingly, they have been described as game changers.But as their popularity grew, so did the problems.Most GLP-1 medicines are given as a once-weekly injection into the arm, thigh, or abdomen. Treatment usually starts with a low dose and is gradually increased. Within a few weeks, many users notice a change: appetite wanes, portion sizes decrease, and the constant mental chatter surrounding food softens. For some, the scale is starting to change for the first time in years.

Doctors stress, however, that these drugs are not magic or an accessory to a casual lifestyle. Weight usually returns within a year of stopping the drug, as the body’s biological drive to regain lost weight reasserts itself. Without regular exercise, especially strength training, patients can lose muscle and fat, a concern in a country where diets are often high in carbohydrates and low in protein.Dr Arun Moondhra, senior consultant physician at Sant Parmanand Hospital Civil Lines, said: “It is suitable for weight loss treatment but should be taken only under medical guidance. If the sale is not restricted, the possibility of abuse is always there.”There are other restrictions. Not everyone responds to GLP-1 therapy, and many people plateau after losing around 15% of their body weight. Side effects such as nausea, bloating, and diarrhea are usually manageable, but rare complications such as gallstones or pancreatitis can occur. Long-term, unsupervised use carries risks.Dr. Moondhra also emphasized that the use of semaglutide will increase exponentially once cheaper generics become available.